Publication: Mesoporous Silica-Based Nanoparticles as Non-Viral Gene Delivery Platform for Treating Retinitis Pigmentosa.
Loading...
Identifiers
Date
2022-04-13
Authors
Valdés-Sánchez, Lourdes
Borrego-González, Sara
Montero-Sánchez, Adoración
Massalini, Simone
de la Cerda, Berta
Díaz-Cuenca, Aránzazu
Díaz-Corrales, Francisco J
Advisors
Journal Title
Journal ISSN
Volume Title
Publisher
Abstract
Gene therapy is a therapeutic possibility for retinitis pigmentosa (RP), in which therapeutic transgenes are currently delivered to the retina by adeno-associated viral vectors (AAVs). Although their safety and efficacy have been demonstrated in both clinical and preclinical settings, AAVs present some technical handicaps, such as limited cargo capacity and possible immunogenicity in repetitive doses. The development of alternative, non-viral delivery platforms like nanoparticles is of great interest to extend the application of gene therapy for RP. Amino-functionalized mesoporous silica-based nanoparticles (N-MSiNPs) were synthesized, physico-chemically characterized, and evaluated as gene delivery systems for human cells in vitro and for retinal cells in vivo. Transgene expression was evaluated by WB and immunofluorescence. The safety evaluation of mice subjected to subretinal injection was assessed by ophthalmological tests (electroretinogram, funduscopy, tomography, and optokinetic test). N-MSiNPs delivered transgenes to human cells in vitro and to retinal cells in vivo. No adverse effects were detected for the integrity of the retinal tissue or the visual function of treated eyes. N-MSiNPs were able to deliver a therapeutic transgene candidate for RP, PRPF31, both in vitro and in vivo. N-MSiNPs are safe for retinal delivery and thus a potential alternative to viral vectors.
Description
MeSH Terms
DeCS Terms
CIE Terms
Keywords
PRPF31, gene therapy, mesoporous silica, nanoparticles, retinitis pigmentosa